|
ATG4A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.61530011588695E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.61319999580911E-08 |
| Normal-vs-Stage2 |
1.148810E-01 |
| Normal-vs-Stage3 |
2.4917845564687E-12 |
| Normal-vs-Stage4 |
4.09883238461362E-12 |
| Stage1-vs-Stage2 |
1.904260E-02 |
| Stage1-vs-Stage3 |
3.842400E-03 |
| Stage1-vs-Stage4 |
1.298900E-03 |
| Stage2-vs-Stage3 |
3.219900E-04 |
| Stage2-vs-Stage4 |
3.63450000000487E-05 |
| Stage3-vs-Stage4 |
1.725170E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.87170279275506E-11 |
| Normal-vs-AfricanAmerican |
2.383200E-03 |
| Normal-vs-Asian |
5.89520000038313E-07 |
| Caucasian-vs-AfricanAmerican |
6.625800E-01 |
| Caucasian-vs-Asian |
8.099600E-01 |
| AfricanAmerican-vs-Asian |
6.063000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.63230000019377E-08 |
| Normal-vs-Female |
2.78030043432409E-10 |
| Male-vs-Female |
9.301200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.72370000051103E-07 |
| Normal-vs-Age(41-60Yrs) |
5.03590502631823E-11 |
| Normal-vs-Age(61-80Yrs) |
2.71929999962062E-07 |
| Normal-vs-Age(81-100Yrs) |
1.680400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.648300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.950000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.472600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.811400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.857200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.055600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.55829999999902E-05 |
| Classical-VS-Follicular |
1.41289999999739E-06 |
| Classical-VS-Other |
9.896800E-01 |
| Classical-VS-Normal |
2.03840277990253E-11 |
| Tall-VS-Follicular |
1.92950100341704E-11 |
| Tall-VS-Other |
3.240800E-01 |
| Tall-VS-Normal |
1.11022302462516E-15 |
| Follicular-VS-Other |
1.295430E-01 |
| Follicular-VS-Normal |
1.696830E-01 |
| Other-VS-Normal |
8.311700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.91869999952321E-07 |
| Normal-vs-N1 |
2.20229945391281E-10 |
| N0-vs-N1 |
9.581200E-04 |
|
|
